Drug Trial Radar · NCT03621280
Open-label Treatment in Cushing's Syndrome
Last checked: Nov 20, 2026Latest source record: Jun 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
51
Actual
Start
Jan 7, 2019
Primary completion
Dec 31, 2022
Study completion Dec 31, 2022
Sponsor
- Lead sponsor
- Cortendo ABIndustry
- Sponsor type
- Industry
- First posted
- Aug 8, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a long-term, open-label extension study of levoketoconazole in participants with endogenous Cushing's Syndrome.
Conditions
- Cushing Syndrome
- Cushing Disease
Interventions
LevoketoconazoleDrug
Levoketoconazole up to 1200 mg daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportions of Participants With Mean Urinary Free Cortisol (mUFC) Categorization Based on Upper Limit of Normal (ULN)Time frame: From parent study Baseline to final study visit or up to a maximum of 3 years, whichever comes first.
Locations
30 sites in 11 countries. Site status is shown where the registry gives one.
The Center for Diabetes and Endocrine Care
Fort Lauderdale, Florida
Emory University
Atlanta, Georgia
Washington University School of Medicine
St Louis, Missouri
University of New Mexico HSC - HSC Sponsored Projects Office
Albuquerque, New Mexico
Columbia University Medical Center
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Cleveland Clinic
Cleveland, Ohio
Oregon Health & Science University
Portland, Oregon
Sveti Georgy University Hospital Clinic of Endocrinology and Metabolic Diseases
Plovdiv, Bulgaria
Alexandovska University Hospital
Sofia, Bulgaria
University Specialized Hospital for Active Treatment in Endocrinology
Sofia, Bulgaria
APHM Hôpital de la Conception
Marseille, France
General Hospital of Athens Evangelismos Department of Endocrinology and Diabete
Athens, Greece
Hippokration General Hospital Endocrinology and Diabetes Department
Thessaloniki, Greece
Semmelweis Egyetem II. Belgyógyászati Klinika
Budapest, Hungary
Bnai Zion Medical Center Endocrinology Institute
Haifa, Israel
Rabin Medical Center, Beilinson Campus
Petah Tikva, Israel
Tel Aviv-Sourasky Medical Center Institute Endocrinology Metabolism & Hypertension
Tel Aviv, Israel
Clinica Endocrinologia malattie del Metabolismo
Ancona, Italy
AOU Policlinico G. Martino Sezione di Endocrinologia
Messina, Italy
Via Sergio Pansini 5 Uni Naples FedericoII Dept of Molecular&Clinical Endocrinology&Oncology
Naples, Italy
Policlinico Universitario Sant'Andrea
Roma, Italy
University of Turin
Turin, Italy
Erasmus Medical Center
Rotterdam, Netherlands
Instytut Centrum Zdrowia Matki Polki
Lodz, Poland
Institutul National de Endocrinologie C.I. Parhon
Cluj-Napoca, Romania
Spitalul Clinic Judetean de Urgenta Cluj-Napoca
Cluj-Napoca, Romania
Spitalul Clinic Judetean Mures
Târgu Mureş, Romania
Hospital Universidad De La Ribera
Alzira, Spain
Hospital Universitario Ramón y Cajal
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.